- 1. Secure our presence in the generics business.
- 2. Achieve a stronger position in the hyperuricemia market, centered on Uralyt.
- 3. Contribute to society through proprietary developments toward drug discovery.
The goal of the Chemiphar Group is to make a difference in society by providing pharmaceutical drugs and health-related services to help people become and remain healthy.
May 31, 2022 | Notice of the 90th Ordinary General Meeting of Shareholders. (pdf, 353KB) |
---|---|
May 26, 2022 | |
May 16, 2022 | |
May 13, 2022 | Summary of Consolidated Financial Results for the FY2021. (pdf, 173KB) |
May 13, 2022 |
March 08, 2022 | DFP and Chemiphar conclude license agreement for DFP-14323(pdf, 136KB) |
---|---|
January 31, 2022 | |
January 31, 2022 | Chemiphar announced third quarter business summary FY2021. (pdf, 314KB) |
December 22, 2021 | Application for Selection and Listing on the New Prime Market Segment of the TSE. (pdf, 88KB) |
November 15, 2021 | Highlights of second quarter FY2021 business results. (pdf, 820KB) |